Oramed’s Corporate Defense: A Biotech’s Battle for Autonomy
Published on 11/18/2025 at 11:19 | Editorial boerse-global.de
A biotech firm suddenly flush with cash and developing a revolutionary medical treatment typically represents an investor’s ideal scenario. However, the current narrative at Oramed Pharmaceuticals is dominated not by scientific progress, but by a significant corporate power struggle. As the company announces record-breaking profits, its leadership is taking decisive action to shield itself from potential acquisition.
Oramed’s latest financial report has captured industry attention with a dramatic reversal of fortune. For the initial three quarters of 2025, the company posted a substantial profit of $65 million, a stark contrast to the $6.1 million loss previously recorded. This impressive turnaround, however, stems not from product sales but from strategic financial Read more...
